ARIANNA

Window Program

Targeting the PAM50 HER2-enriched phenotype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer

Phase II

Status

Recruiting

Tumour subtype:

HR+

Scenario

Locally Advanced or Metastatic

SPONSOR

SOLTI

COLLABORATORS

Breast Cancer Research Foundation (BCRF) Drug Research Collaborative

PRINCIPAL INVESTIGATORS

Mafalda Oliveira, MD, PhD (Hospital Universitario Vall d’Hebron e Instituto de Oncología Vall d’Hebron (VHIO))
Luis Manso, MD, PhD (Hospital Universitario 12 de Octubre, Madrid)
Charles M Perou, PhD (Lineberger Comprehensive Cancer Center University of North Carolina)

Sites

HOSPITAL CLINIC DE BARCELONA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO FUNDACIÓN DE ALCORCÓN, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, ICO BADALONA, ICO HOSPITALET (DURAN I REYNALS), INSTITUTO VALENCIANO DE ONCOLOGÍA